119.60p
+0.17%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PureTech Health
Its shares trade on LSE under the ticker PRTC.L. It has been listed since 19 June 2015. In the fiscal year to 31 December 2025, it reported revenue of $4.8m and a net loss of $112.2m. At that date it held total assets of $535.6m and shareholders' equity of $312.6m.
PureTech Health Plc is a cross-disciplinary bio-pharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune. The company is headquartered in Boston, Massachusetts. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders, and inflammatory and immunological diseases, among others. Its segments include Internal and Affiliates. The Internal division is focused on advancing a pipeline fueled by discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programs within its Affiliates division that are consolidated operational subsidiaries that have research and development programs. Its wholly owned pipeline includes various candidates, such as LYT-100, LYT-200, LYT-210, Lymphatic Targeting Chemistry Platform, Milk Exosome Platform and Meningeal Lymphatics Platform.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jun 2015
- Employees
- 300
- Website
- puretechhealth.com ↗
Leadership
Pay as last reported
- Ms. Sharon Barber-luiInterim Independent Non-Executive Chairman of the Board$260,000
- Dr. Eric ElenkoPresident, Director
- Mr. Robert LyneInterim Chief Executive Officer
- Dr. Robert LangerCo-Founder, Non-Executive Director$270,000
- Dr. Charles SherwoodGeneral Counsel, Company Secretary
- Mr. Robert HombachDirector
- Dr. Michele HolcombNon-Executive Independent Director$123,653
- Dr. John LamattinaNon-Executive Independent Director$290,000
- Ms. Kiran Mazumdar-ShawNon-Executive Independent Director$235,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 68
- Environment
- 78
- Social
- 99
- Governance
- 28
- Direct emissions (scope 1)
- 3.2 t
- Energy emissions (scope 2)
- 60.1 t
- Value chain emissions (scope 3)
- 75.6 t
- Women in the workforce
- 54%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PureTech Health PLC has a diverse portfolio of innovative healthcare companies focused on developing important solutions for unmet medical needs. The company has a strong track record of transforming scientific discoveries into valuable therapies that address major healthcare challenges. PureTech's approach of building and growing companies from within allows for significant control and alignment with its objectives.
- Additionally, PureTech possesses a robust global network of academic, clinical, and industry partnerships. These collaborations enable access to cutting-edge research, expertise, and resources, strengthening the company's ability to identify and develop promising healthcare technologies.
Weaknesses
- One weakness of PureTech Health PLC is its reliance on the success of its portfolio companies. If any of these companies fail to achieve their anticipated milestones or face regulatory or market challenges, it could have a negative impact on PureTech's overall financial performance and reputation.
- Furthermore, as a company engaged in the healthcare industry, PureTech is subject to stringent regulations and potential legal and ethical controversies. This can create challenges in product development, manufacturing, and commercialization, increasing compliance costs and potentially delaying revenue generation.
Opportunities
- PureTech Health PLC operates in an industry that presents substantial growth opportunities. The increasing global demand for innovative healthcare solutions, driven by demographic shifts and rising healthcare costs, creates a favorable market for the company's products and services.
- Moreover, advancements in scientific research and technology provide an opportune environment for PureTech to leverage its expertise and create novel therapies. Strategic collaborations with academia, research institutions, and industry leaders offer avenues for accessing breakthrough discoveries and expanding the company's pipeline.
Threats
- The healthcare industry is highly competitive, and PureTech Health PLC faces the risk of being outpaced by competitors with similar or superior capabilities. The presence of well-established pharmaceutical and biotechnology companies, as well as the emergence of new players, poses a threat to PureTech's market share and growth prospects.
- Additionally, regulatory hurdles and approval processes can create prolonged timelines and uncertainties in bringing products to market. Delays in obtaining necessary approvals or changing regulatory requirements may hinder PureTech's ability to capitalize on market opportunities effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.